As the Colorado Prescription Drug Affordability Board (PDAB) begins affordability reviews of the five prescription drugs selected earlier this month, it is reaching out to stakeholders to request their engagement in the affordability review process via their Stakeholder Engagement Guide. Specifically, the PDAB is seeking input from patients and caregivers, individuals with scientific and medical training, drug manufacturers, insurance carriers and Pharmacy Benefit Managers (PBMs). Stakeholders are encouraged to engage through weekly office hours with staff, stakeholder meetings, and submission of written or verbal public comment, or voluntary written information.
The Top Reasons Stakeholders Should Engage
CBSA shares the goal of improving the affordability of medicines for patients. However, we remain concerned that any future decision to deem a drug unaffordable or to set a state-mandated upper payment limit (UPL), could have serious unintended consequences on patients’ access to life-saving and life-changing medicines and on the feasibility of…
Click here to view original post
